Akèy › Skleroz an milti relaps-remitan › Kalifòni
Etid klinik pou Skleroz an milti relaps-remitan nan Kalifòni
6 etid pou Skleroz an milti relaps-remitan ap chèche patisipan nan sit nan Kalifòni.
Tèks ofisyèl etid la (Anglè)
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- Stanford Multiple Sclerosis Center, Palo Alto
Ap rekriteFaz 3
Laj 18 a 55 · Tout sèks · Mizajou Sep 16, 2026 · NCT04047628Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
- Local Institution - 0114, Loma Linda
- University of California Davis Health, Sacramento
Ap rekriteFaz 3
Laj 10 a 17 · Tout sèks · Mizajou Sep 10, 2026 · NCT06408259The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
- University of California Irvine Center for Clinical Research, Irvine
Ap rekrite
Laj 22 a 60 · Tout sèks · Mizajou Sep 2, 2026 · NCT06796504Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
- Sandler Neurosciences Building, Neurological Clinical Research Unit, San Francisco
Ap rekriteFaz 1/2
Laj 18 a 55 · Tout sèks · Mizajou Jul 2, 2026 · NCT05359653"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
- University of California, San Francisco, San Francisco
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Oct 31, 2025 · NCT07222618MS-ResearchBiomarkerS
- Cedars-Sinai Medical Center, Los Angeles
Ap rekriteEtid obsèvasyonVolontè an sante akeyiMande peman pou patisipan yo
Laj 18 ak plis · Tout sèks · Mizajou Feb 6, 2024 · NCT05204459Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.